Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult, London, UK, outlines the need for international harmonization and standardized approaches within advanced therapies. By implementing new, consistent standards within the industry, hospitals can more easily adopt or switch to new therapies, which will increase usage of the therapies, lower costs and increase accessibility to patients. Cell and Gene Therapy Catapult has established a network of Advanced Therapy Treatment Centres in the UK and is working with international standards organizations to tackle challenges surrounding standardization in manufacturing, payment and adoption, amongst others. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.
Matthew Durdy is employed by the Cell and Gene Therapy Catapult, London, UK.